This company got off to a solid start this year, reporting at the end of last month a strong first-quarter earnings beat and a full-year outlook raise.
Source
We’re adding to a health insurance stock on the dip that had great earnings
Health
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]
Read More
Health
Making U.S. biotech more competitive with China’s could help rare disease patients, experts say
The growth of China’s biotechnology sector has been staggering. Beijing is pumping money into the industry, backing research efforts and helping launch a new wave of labs and incubators in the country. That’s a problem for the U.S. biotech industry and also affects rare disease patients who are waiting for a cure. Among the experts […]
Read More
Health
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Good morning from San Francisco! It’s day three of the annual JPMorgan Healthcare Conference – the biggest gathering of biotech and pharma execs, investors and analysts in […]
Read More